To evaluate the feasibility of the autoinflammatory disease activity index (AIDAI) as a tool to assess disease activity in patients with hereditary recurrent fever syndromes (HRFs) treated with canakinumab.
Use of the Auto-inflammatory Disease Activity Index to monitor disease activity in patients with colchicine-resistant Familial Mediterranean Fever, Mevalonate Kinase Deficiency, and TRAPS treated with canakinumab / Koné-Paut, I., Piram, M., Benseler, S., Kuemmerle-Deschner, J.B., Jansson, A., Rosner, I., Tommasini, A., Murias, S., Karadag, O., Levy, J., Mccreddin, S., Migliaccio, M., Benedetti, F.D.. - In: JOINT BONE SPINE. - ISSN 1297-319X. - 89:6(2022), pp. 105448."-"-105448."-". [10.1016/j.jbspin.2022.105448]
Use of the Auto-inflammatory Disease Activity Index to monitor disease activity in patients with colchicine-resistant Familial Mediterranean Fever, Mevalonate Kinase Deficiency, and TRAPS treated with canakinumab
Tommasini, Alberto;
2022-01-01
Abstract
To evaluate the feasibility of the autoinflammatory disease activity index (AIDAI) as a tool to assess disease activity in patients with hereditary recurrent fever syndromes (HRFs) treated with canakinumab.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1297319X22001087-main.pdf
accesso aperto
Tipologia:
Documento in Versione Editoriale
Licenza:
Creative commons
Dimensione
1.5 MB
Formato
Adobe PDF
|
1.5 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
